Breakthrough Alert!  Bringing New Hope to Relapsed and Refractory Multiple Myeloma Patients

Breakthrough Alert!  Bringing New Hope to Relapsed and Refractory Multiple Myeloma Patients

Multiple Myeloma

   A recent milestone at the First Affiliated Hospital of Sun Yat-sen University in China marks a groundbreaking achievement in the treatment of relapsed and refractory multiple myeloma (R/RMM). Professor Li Juan and her team from the Hematology Department have successfully conducted the hospital’s inaugural Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) for this challenging condition, ushering in a new era of treatment prospects for R/RMM patients.

    Relapsed and refractory stages are often unavoidable in the progression of Multiple Myeloma, with limited treatment options and poor prognoses for patients upon entry into this phase. CAR-T therapy, a novel precision-targeted approach in cancer treatment, involves genetically engineering T-cells to restore their functionality, effectively targeting tumors with remarkable precision, speed, and efficiency. Both domestic and international studies have shown promising results for CAR-T therapy in R/RMM patients, making it one of the most effective treatments available for this condition.

     The first patient to undergo CAR-T therapy at our hospital was a 42-year-old male diagnosed with multiple myeloma two years prior at another medical institution. After undergoing conventional treatments for a period, including autologous hematopoietic stem cell transplantation, his disease unfortunately relapsed nine months post-transplant. Despite immediate intervention by experts, the disease was only briefly controlled, and the patient’s prognosis declined rapidly as he entered the refractory stage, with an estimated survival period of less than 20 months.

    With the approval of China’s first CAR-T BCMA multiple myeloma product, FUCASO, the patient and his family, after thorough consultations with healthcare professionals, opted for CAR-T therapy. Prior to treatment, the hematology team meticulously discussed potential complications and collaborated with relevant departments to establish comprehensive contingency plans. Following rigorous screening, lymphocyte collection, CAR-T cell preparation, and infusion, the patient smoothly progressed through the CAR-T cell infusion stage as planned.

     By the third week post-infusion, the patient experienced gradual relief from rib pain. On the 28th day post-infusion, bone marrow examination revealed no myeloma cells, and related indicators along with a full-body PET/CT scan indicated negativity for extramedullary lesions, showcasing significant treatment efficacy. The patient was successfully discharged, marking a triumphant milestone in his journey towards recovery.

     According to experts, with the continuous refinement of national guidelines for CAR-T cell therapy, the formal introduction of China’s first CAR-T product for myeloma treatment offers promising prospects for extending the survival period of domestic patients with refractory and relapsed multiple myeloma.

#CARTTherapy #MultipleMyeloma #CancerTreatment #HopeForPatients #MedicalBreakthrough #Hematology #PrecisionMedicine #HealthcareInnovation #MedicalResearch #SurvivalRates

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

9 months ago CAR-T

Hope For Patients of Gastric Cancer And Pancreatic Cancer – CT041 Typical Cases and Achievements

🔬✨Hope For Patients of Gastric And Pancreatic Cancer – CT041 Typical Cases and Achievements ✨🔬

 

Patient 1: 53-year-old Male

Gastric Cancer,
Pancreatic Cancer

Advanced gastric cancer with liver, lung, bone metastases, and multiple lymph nodes and peritoneal metastases. Previously treated with 2 systemic therapies including PD-1 antibodies, CLDN18.2 expression 60% (3+). After CAR-T therapy, tumor size decreased by nearly 50%, achieving sustained remission for 32 weeks.

 

Patient 2: 57-year-old Female

Gastric Cancer,
Pancreatic Cancer

Gastric cancer with peritoneal metastasis and Sister Mary Joseph’s nodule (malignant tumor metastasis forming a nodule-like lesion in the umbilicus). Previously received third-line therapy including PD-1 antibodies, CLDN18.2 expression 80% (2+). Achieved partial remission after CAR-T therapy, with sustained response exceeding 56 weeks.

 

🏆 CT041 Achievements 🏆

– In May 2020, FDA approved CT041 for investigational new drug (IND) authorization for the treatment of claudin18.2-positive gastric, gastroesophageal junction, or pancreatic adenocarcinoma patients.

– In 2020, received orphan drug designation from the U.S. FDA for the treatment of gastric/gastroesophageal junction cancer.

– In 2021, granted orphan drug designation by the European Medicines Agency (EMA) and qualified for the European PRIME program.

– In 2022, received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA.

– On March 3, 2022, approved by the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) to enter Phase II clinical trials!

We are currently urgently recruiting patients with B-cell lymphoma, T-cell lymphoma, T-cell leukemia (T-ALL), acute lymphoblastic leukemia, myeloma, and other types of cancer!

we are currently urgently recruiting patients with B-cell lymphoma, T-cell lymphoma, T-cell leukemia (T-ALL), acute lymphoblastic leukemia, myeloma, and other types of cancer!

You can send electronic copies or photos of genetic testing reports and diagnostic reports to the email address:

doctor.huang@globecancer.com,

or WhatsApp+8613717959070

The Medical Department will contact you as soon as they receive the reports.

 

#CancerResearch #Immunotherapy #CART #MedicalBreakthrough #ClinicalTrials #FDAApproval #OrphanDrug #HealthcareInnovation #GastricCancer #PancreaticCancer #CT041 #MedicalAdvancement #RegenerativeMedicine #RMAT #EMAApproval #NMPAApproval #MedicalScience #PrecisionMedicine #PatientCare

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

9 months ago CAR-T

Breaking News: Another Milestone for Domestic CAR-T Therapy! Clinical Benefit Rate Reaches 71.4% in CT041 Trials, Challenging Gastric and Pancreatic Cancers with Astonishing Results!

🎉 Breaking News: Another Milestone for Domestic CAR-T Therapy! Clinical Benefit Rate Reaches 71.4% in CT041 Trials, Challenging Gastric and Pancreatic Cancers with Astonishing Results! 🚀

Gastric Cancer， Pancreatic Cancer

A burgeoning therapeutic target for gastric cancer—Claudin 18.2, its discovery has also opened a new chapter in targeted therapy for gastric cancer. If we talk about the hottest cell immunotherapy in recent years, it has to be chimeric antigen receptor T-cell (CAR-T) therapy. Based on this, Chinese researchers have developed the world’s first CAR-T cell therapy targeting Claudin18.2—CT041.

 

CT041, as the first CAR-T cell therapy targeting Claudin18.2, made its debut at the 2019 ASCO Annual Meeting. Among 12 patients with metastatic adenocarcinoma (7 gastric cancer, 5 pancreatic cancer) treated with Claudin18.2-targeting CAR T-cell therapy, no severe adverse events, treatment-related deaths, or serious neurotoxicity were reported. Among the 11 evaluated patients: 1 (gastric adenocarcinoma) achieved complete remission; 3 (2 gastric adenocarcinoma, 1 pancreatic adenocarcinoma) achieved partial remission; 5 had stable disease; and 2 experienced disease progression. The overall objective response rate was 33.3%.

 

At the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) held on January 19, 2024, SciGen showcased a clinical study of Claudin18.2-targeting autologous CAR-T cell therapy CT041 (satri-cel), reporting results from the dose escalation phase of the ELIMYN18.2 1b clinical trial conducted in the United States for the treatment of gastric/esophagogastric junction adenocarcinoma (GC/GEJ) or pancreatic cancer (PC).

 

This single-arm, open-label phase 1b/2 study primarily evaluated the safety and efficacy of CT041 in patients with advanced Claudin18.2-positive gastric/esophagogastric junction adenocarcinoma (GC/GEJ, progressing after at least second-line treatment or intolerant) or pancreatic cancer (PC, progressing after at least first-line treatment or intolerant).

 

Nineteen patients (9 GC/GEJ patients, 12 PC patients) received CT041 treatment at doses ranging from 250 to 600×106 cells: dose 1: 250-300×106 (n=6), dose 2: 375-400×106 (n=6), dose 3: 600×106 (n=7). All patients had received systemic therapy, with 85.7% of GC/GEJ patients and 58.3% of PC patients receiving ≥3 lines of systemic therapy. The median number of metastatic organs for all patients was 2, with at least one prior infusion. Clinical benefit rate included complete remission [CR], partial remission [PR], and stable disease [SD] ≥180 days.

 

As of September 15, 2023, with a median follow-up of 8.9 months, across all dose groups, the confirmed objective response rate (ORR) for gastric/esophagogastric junction adenocarcinoma patients was 42.9% (3/7); clinical benefit rate (CBR) was 57.1% (4/7); median progression-free survival (mPFS) and median duration of response (mDOR) were 5.7 months and 6.9 months, respectively. Additionally, the median overall survival (mOS) for gastric/esophagogastric junction adenocarcinoma or pancreatic cancer patients was 8.9 months. In dose level 3 (DL3), one gastric/esophagogastric junction adenocarcinoma patient achieved complete remission (CR). The clinical benefit rate for gastric/esophagogastric junction adenocarcinoma or pancreatic cancer patients was 71.4% (5/7), with a median OS of 12.9 months.

 

In summary, #CT041, as the first autologous #Claudin182 CAR-T cell therapy, demonstrates encouraging safety and shows promising preliminary efficacy in Claudin18.2-positive advanced GC/GEJ and PC patients who have received multiple prior treatments.

 

You can send electronic copies or photos of genetic testing reports and diagnostic reports to the email address: doctor.huang@globecancer.com, or click on the WhatsApp+8613717959070 icon on the homepage. The Medical Department will contact you as soon as they receive the reports.

 

🌟 #CART #Immunotherapy #CT041 #CancerResearch #ClinicalTrials #GastricCancer #PancreaticCancer #SciGen #ASCOGI2024

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

10 months ago CAR-T

Breakthrough! Chinese Novel CAR-T Therapy Kills Tumors and Prevents Relapse!

🌟✨ **Breakthrough! Chinese Novel CAR-T Therapy Kills Tumors and Prevents Relapse!** ✨🌟

CAR-T Therapy

🔬 On January 2, 2024, a groundbreaking clinical study from China was published in *Nature*. This study, employing engineering design, enables CAR-T cells to secrete Interleukin-10 (IL-10), thereby enhancing metabolism within the tumor microenvironment. The modified IL-10 CAR-T cells increase oxidative phosphorylation in a mitochondrial acetoacetate carrier-dependent manner, resulting in complete regression of solid tumors and metastatic cancers, including colon cancer, breast cancer, melanoma, and pancreatic cancer. This breakthrough research offers new hope for cancer patients.

🌱 **The Miracle of IL-10** 🌱

The secretion of IL-10 promotes the proliferation and effector functions of CAR T cells, leading not only to the regression of solid tumors but also inducing stem cell-like memory responses in lymphoid organs, providing enduring protection against tumor re-attack. Specifically, IL-10 HER2 CAR-T cells achieved complete regression of MC38-HER2 tumors in mice, with a cure rate of 90%. In the case of melanoma, IL-10 TRP-1 CAR-T cells achieved a clearance rate of 60%, with significant success in treating the orthotopic B16F10 melanoma model.

🦠 **A Weapon against Relapse** 🦠

In addition to complete regression of solid tumors, IL-10 CAR-T cells demonstrated the ability to prevent relapse in immunodeficient mice. Mice treated with IL-10 CD19 hCAR-T cells for Raji or PANC1-CD19 tumors exhibited complete tumor regression without relapse, indicating stronger anti-tumor capabilities of IL-10 CAR-T cells in xenograft models. Particularly noteworthy is the effective elimination of pancreatic ductal adenocarcinoma (PDAC) tumors by IL-10 CD19 hCAR-T cells, resulting in complete response in all treated mice.

💊 **A Revolutionary Treatment Approach** 💊

These findings suggest that IL-10-expressing CAR-T cells are an effective immunotherapy against various solid tumors, capable of achieving complete regression in multiple synthetic and xenograft tumor models. What’s more exciting is that preliminary results indicate the metabolism-enhanced IL-10 CD19 CAR-T cell therapy developed by Leman Biotech requires extremely low treatment doses, consistently achieving complete remission in numerous relapsed/refractory lymphoma or leukemia patients, paving the way for a new era in cancer treatment.

✨ **A Beacon of Hope** ✨

This breakthrough study brings hope to cancer patients and demonstrates the immense potential of CAR-T therapy in cancer treatment. Looking ahead, further advancements in this technology promise to provide more opportunities for recovery and survival to patients worldwide. Let’s anticipate more breakthroughs together and strive towards conquering cancer

 

To assess whether the condition is suitable for CAR-T therapy, you can submit Advanced Medicine in China for preliminary evaluation!

Email: doctor.huang@globecancer.com,

WhatsApp: +8613717959070

#all #CARTtherapy #CancerTreatment #RRMM #IL10 #Tumor #Nature #MedicalBreakthrough #CARTCELL #coloncancer #breastcancer #melanoma #pancreatic 🌟🔬💊

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

10 months ago CAR-T

Haematologica Spotlight：A Chinese team published the largest-scale pediatric-style regimen treatment for adult Ph-negative ALL

🔬 *Haematologica Spotlight* 🔬

A Chinese team published the largest-scale pediatric-style regimen treatment for adult Ph-negative ALL

Acute Lymphoblastic Leukemia (ALL)

    is a hematological malignancy characterized by the proliferation of immature lymphoid cells in the bone marrow, peripheral blood, and extramedullary sites. While the prognosis for childhood ALL is relatively favorable, with a 5-year overall survival rate of 80-90%, adult ALL poses greater challenges. Approximately 20-30% of adult acute leukemias are ALL, with about two-thirds being Philadelphia chromosome-negative (Ph-negative) ALL. Conventional adult ALL treatments have shown high remission rates but also high relapse rates and poor long-term survival.

Haematologica

Inspired by the success of pediatric ALL treatments, especially in adolescent and young adult patients, the Hematology Center at the

Chinese Academy of Medical Sciences and Peking Union Medical College Hospital

    embarked on a groundbreaking journey. Their pioneering research, recently published in *Haematologica*, presents the results of the largest prospective cohort study in China investigating the efficacy of a pediatric-inspired regimen in adult Ph-negative ALL patients.

 

The study, led by Dr. Wang Jianxiang and his team,

    evaluated the IH-2014 regimen’s effectiveness in 415 newly diagnosed adult Ph-negative ALL patients treated between April 2014 and December 2021, with a median age of 27 years (range 14-65 years) and a median follow-up of 40.8 months. The overall 5-year overall survival (OS) and disease-free survival (DFS) rates were 53.8% and 51.1%, respectively, with a chemotherapy-related mortality rate of 3.6%.

 

Patients achieving complete remission (CR)

    after induction therapy with available bone marrow minimal residual disease (MRD) data were categorized based on diagnostic risk: standard-risk (SR) MRD-negative (<0.01%) in 73 patients (18.8%), SR MRD-positive (≥0.01%) in 69 patients (17.7%), high-risk (HR) MRD-negative in 120 patients (30.8%), and HR MRD-positive in 127 patients (32.6%). The 5-year OS rates for these groups were 82.6%, 58.7%, 58.3%, and 36.1%, respectively (P＜0.001), with corresponding cumulative relapse rates of 24.2%, 41.1%, 36.3%, and 50.1% (P＜0.001). Multivariate analysis identified age ≥40 years and MRD positivity after induction as independent adverse prognostic factors for OS and DFS.

 

In conclusion, the IH-2014 regimen demonstrates significant efficacy and good tolerability in adult Ph-negative ALL patients, with younger patients (<40 years) benefiting more prominently. Induction treatment response combined with MRD levels serves as a valuable prognostic indicator for long-term survival and relapse, guiding allogeneic hematopoietic stem cell transplantation decisions in patients achieving first complete remission (CR1).

 

This study marks a pivotal milestone in advancing adult ALL treatment strategies, showcasing China’s remarkable progress in the field of hematology. Stay tuned for more groundbreaking research from our team!

 

🎉To assess whether the condition is suitable for CAR-T therapy, you can submit Advanced Medicine in China for preliminary evaluation!

Email: doctor.huang@globecancer.com,

WhatsApp: +8613717959070

 

🌟 #Haematologica #LeukemiaTreatment #PediatricInspiration #ALL #AcuteLymphoblasticLeukemia #LymphoblasticLeukemia #Leukemia 

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

10 months ago CAR-T

Exciting News Alert! China’s New TCR-T Product IND Approved for Synovial Sarcoma!

🌟 Exciting News Alert! China’s New TCR-T Product IND Approved for Synovial Sarcoma! 🌟

synovial sarcoma

“Engineered T Cell Receptor-T Cell Therapy,” or “TCR-T (engineered T cell receptor-T cell, TCR-T) cell therapy,” involves the extraction of peripheral blood mononuclear cell (PBMC) samples from patients, followed by genetic engineering to introduce selected high-affinity T cell receptors (TCRs) into T cells. This enables them to seek out and specifically recognize tumor antigens, effectively targeting and killing cancer cells.

In early 2022, the Food and Drug Administration (FDA) in the United States approved a TCR-T therapy called “Kimmtrack” for treating uveal melanoma, marking a significant milestone in solid tumor treatment.

 

Recently, the prestigious international journal “Cell Rep Med” reported the Phase I clinical trial results of China’s first investigational new drug (IND) approved by the FDA for TCR-T cell therapy — TAEST16001. This groundbreaking research represents a crucial step forward in the clinical translation of adoptive T cell immunotherapy for advanced soft tissue sarcoma and holds the potential to become the world’s second marketed TCR-T cell therapy targeting solid tumors!

Cell Rep Med

China’s first TCR-T product IND approval takes aim at synovial sarcoma.

TAEST16001,

           developed independently by Xiangxue Life Sciences, is a TCR-T cell product. The Phase I clinical trial enrolled 12 patients with advanced soft tissue sarcomas who were HLA-A*02:01 positive and expressed the NY-ESO-1 antigen. Among them, 10 patients had synovial sarcoma, while 2 had liposarcoma (1 myxoid liposarcoma and 1 dedifferentiated liposarcoma), with a median age of 33 (25-67) years. 58.3% (7/12) of patients were male. Before enrollment, 83.3% of patients had received at least two types of chemotherapy. After enrollment, all patients underwent modified lymphocyte clearance surgery followed by infusion treatment with TAEST16001 cells.

 

After a median treatment duration of 43 days, 9 out of 12 patients (75%) showed tumor regression (Figure 1), with a median time to response (TTR) of 1.9 months and a median duration of response of 13.1 months. Six patients (50%) exhibited sustained tumor burden reduction after the first radiological assessment. In the primary analysis, 5 out of 12 patients achieved partial responses, resulting in an objective response rate (ORR) of 41.7% (95% CI, 15.2–72.3). Disease stabilization was observed in 5 cases [41.7% (95% CI, 15.2–72.3)], yielding a disease control rate of 83.3% (95% CI, 51.6–97.9). The median progression-free survival (PFS) was 7.2 months (95% CI, 2.5–11.8).

TCR-T Therapy

How to Seek TCR-T Therapy Assistance

Several TCR-T therapies under development in China are urgently recruiting patients with hepatitis B virus-related liver hepatocellular carcinoma, head and neck tumors (oral cancer, laryngeal cancer, etc.), advanced cervical cancer, and anal cancer.

If you wish to assess whether your condition is suitable for CAR-T therapy, you can submit your pathological reports, treatment history, and discharge summaries to

<Advanced Medicine in China> doctor.huang@globecancer.com for preliminary evaluation.

or click on the WhatsApp+8613717959070

 

Stay tuned for more updates on this groundbreaking advancement in cancer treatment! 🌟

 

#CancerResearch #TCRTtherapy #SynovialSarcoma #MedicalInnovation

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

10 months ago CAR-T

Chinese Hengrui Pharmaceuticals ‘s indication for cervical cancer has been approved for clinical trials.

🌟 Chinese Hengrui Pharmaceuticals ‘s indication for cervical cancer has been approved for clinical trials.🌟

cervical cancer

🏥💊（Jiangsu Hengrui Pharmaceuticals Co., Ltd）Hengrui Pharmaceutical’s PD-L1 inhibitor Atezolizumab injection combined with concurrent chemoradiotherapy for the treatment of locally advanced cervical cancer has been approved for open, multicenter Phase II clinical trials.

Atezolizumab

🌸🎀#Cervical cancer is the fourth most common cancer in women globally, mainly caused by persistent infection with high-risk human papillomavirus (#HPV). Although the widespread implementation of #cervicalcancer screening and the availability of HPV vaccines have reduced the incidence of cervical cancer in developed countries, it remains one of the common malignant tumors in women.

 

🏥💊Atezolizumab injection is a humanized anti-PD-L1 monoclonal antibody independently developed by Hengrui Medicine. It is the first PD-L1 inhibitor approved for the treatment of small cell lung cancer in China. By specifically binding to the PD-L1 molecule, it blocks the PD-1/PD-L1 pathway that leads to tumor immune tolerance, reactivating the immune system’s anti-tumor activity and achieving the goal of tumor treatment.

The Lancet Oncology

🌸🎀Atezolizumab injection has been studied in various fields, including small cell lung cancer, #NSCLC non-small cell lung cancer, esophageal cancer, liver cancer, and cervical cancer. It has shown promising efficacy in small cell lung cancer. Based on the results of the SHR-1316-III-301 study, the application for the market approval of Atezolizumab injection combined with chemotherapy as first-line treatment for extensive-stage small cell lung cancer has been accepted and approved in China in March 2023. The study results have been published in the top international medical journal “The Lancet Oncology,” and the original research from China has been internationally recognized.

🏢💊Jiangsu Hengrui Pharmaceuticals Co., Ltd is committed to advancing the clinical research of the PD-L1 inhibitor Atezolizumab injection, bringing more innovative and effective treatment options for cervical cancer patients. Stay tuned for our progress!

Hengrui Pharmaceutical

🚑In addition to Cervical cancer, we are currently urgently recruiting patients with B-cell lymphoma, T-cell lymphoma, T-cell leukemia (T-ALL), acute lymphoblastic leukemia, myeloma, and other types of cancer!

You can send electronic copies or photos of genetic testing reports and diagnostic reports to the 📩email address: doctor.huang@globecancer.com📩, or click on the ✉️WhatsApp+8613717959070✉️ icon on the homepage. The Medical Department will contact you as soon as they receive the reports.

#CervicalCancerTreatment #Atezolizumab #HengruiMedicine #ClinicalTrials #CancerTreatment #cervical #cervicalcancer #chinesemedicine #newdrug #Lancet #TheLancetOncology

 

📩References：　　

[1]gco.iarc.fr(WHO statistics)

　　[2]Rose PG,Bundy BN,Watkins EB,Thigpen JT,Deppe G,Maiman MA,Clarke-Pearson DL,Insalaco S:Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.N Engl J Med1999,340(15):1144-1153.

　　[3]Pfaendler KS,Tewari KS:Changing paradigms in the systemic treatment of advanced cervical cancer.Am J Obstet Gynecol2016,214(1):22-30.

　　[4]Liu C,Lu J,Tian H,Du W,Zhao L,Feng J,Yuan D,Li Z:Increased expression of PDL1by the human papillomavirus16E7oncoprotein inhibits anticancer immunity.Mol Med Rep2017,15(3):1063-1070.

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

10 months ago CAR-T

Chinese Exciting Good News Update in Lung Cancer Treatment! ORR: 78.6%

Chinese Exciting Good News Update in Lung Cancer Treatment! ORR: 78.6%

Meet Sunvozertinib, the game-changer in advanced lung cancer therapy!

Sunvozertinib, NSCLC

This groundbreaking oral medication, a novel irreversible EGFR-TKI, targets multiple EGFR mutation subtypes with remarkable precision. What’s more? Sunvozertinib is now the FIRST and ONLY EGFR-TKI approved for treating late-stage NSCLC with EGFR exon20ins mutations!

At the 2023 ESMO Conference, fresh data from early trials of Sunvozertinib’s frontline treatment for EGFR exon20ins-mutated advanced NSCLC were unveiled, and the results were jaw-dropping! With an astounding Objective Response Rate (ORR) of 78.6% and a median Progression-Free Survival (PFS) of 12.4 months at the recommended dose (300mg QD), Sunvozertinib once again set a new benchmark in this field, offering a superior treatment option for newly diagnosed patients with EGFR exon20ins mutations!

Let’s dive into a real success story: A 35-year-old male diagnosed with late-stage NSCLC harboring EGFR exon20ins mutations, along with metastases to the brain, liver, and bones. After showing stable disease (SD) following two cycles of platinum-based chemotherapy, he switched to Sunvozertinib. Just one month into treatment, a follow-up chest CT scan revealed a remarkable 34% reduction in the size of the left lower lobe lesion, with lung lesions shrinking from 29mm×26mm to 19mm×15mm (see image). Multiple nodules in the lungs and pleura also decreased in size, along with liver lesions. Evaluation: Partial Response (PR)!

Lung Cancer

Noteworthy is the impeccable safety profile of Sunvozertinib, with no significant adverse effects reported during treatment. As of this post, the patient continues to receive Sunvozertinib monotherapy with promising outcomes!

With breakthroughs in targeted therapies for EGFR exon20ins-mutated NSCLC, several new drugs are actively exploring frontline treatment options. The early study results of Sunvozertinib’s frontline therapy for EGFR exon20ins-mutated advanced NSCLC have once again rewritten the records in this field, providing new treatment guidelines for these patients!

#LungCancerAwareness #Sunvozertinib #EGFRexon20ins #NSCLC #TargetedTherapy #MedicalBreakthroughs #HealthcareInnovation #lungs #lung #lungcancer #chinesemedicine #EGFR

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

10 months ago CAR-T

Breakthrough in Cancer Treatment in CHINA: TX103 CAR-T Approved for Clinical Use Against Recurrent Brain Gliomas

🔬”Breakthrough in Cancer Treatment in CHINA: TX103 CAR-T Approved for Clinical Use Against Recurrent Brain Gliomas”🔬🧠

Brain Gliomas

✨ Exciting news in cancer research! Fuzhou Tuoxin Tiancheng Biotech’s TX103 CAR-T, a revolutionary therapy for recurrent stage 4 gliomas, has received clinical approval. 🌟 🧠

#CancerTreatment #MedicalInnovation #TX103CAR_T #CAR_T #Tumor #solidtumor #brainglioma #glioma

 

Article:

Fuzhou Tuoxin Tiancheng Biotech Co., Ltd. (“Tuoxin Tiancheng”) has achieved a significant milestone with the clinical approval of their “TX103 Chimeric Antigen Receptor T-cell Injection” (TX103 CAR-T) for the treatment of recurrent or progressive stage 4 brain gliomas.🧠

 

TX103 CAR-T is a targeted therapy focusing on B7-H3. The B7-H3 target belongs to the B7 ligand family, showing excessive expression in various cancers while maintaining low or no expression in normal tissues. B7-H3 possesses non-immunogenic functions such as promoting migration and invasion, angiogenesis, chemotherapy resistance, endothelial-to-mesenchymal transition, and influencing tumor cell metabolism. Its expression in tumors is associated with poor prognosis, making it valuable in tumor immunotherapy.🧠

 

The therapy has already been approved for clinical trials in both China and the United States, with this recent approval marking a new indication. In August 2022, TX103 received clinical approval for the treatment of late-stage solid tumor patients who are TX103 positive, have failed standard treatments, or experienced intolerable toxicity after standard treatments with a confirmed pathological diagnosis.🧠

 

In September of the previous year, Tuoxin Tiancheng announced that their TX103 CAR-T cells, in collaboration with Tcelltech in the United States, received FDA approval for Investigational New Drug (IND) status for the treatment of malignant brain gliomas. This achievement represents a crucial milestone in Tuoxin Tiancheng’s efforts to address solid tumor treatments and promote internationalization. According to a Tuoxin Tiancheng press release, early clinical trial studies with TX103 in treating recurrent malignant brain gliomas demonstrated promising safety and efficacy signals. Furthermore, TX103 CAR-T for the treatment of malignant brain gliomas received orphan drug designation from the FDA in June 2023.🧠

Tuoxin Tiancheng

Tuoxin Tiancheng is a clinical-stage innovative biopharmaceutical company focused on developing T cell immunotherapy products. Founded by Professor Chen Lieping, a pioneer in tumor immunology, and Professor Huang Gangxiong, an expert in immunotherapy, the company is dedicated to advancing innovative technologies and drugs in tumor immunotherapy and immunocellular therapy. With a professional team covering scientific research, technical development, quality management, production processes and registration, the company has taken a significant step forward with this clinical approval. We look forward to Tuoxin Tiancheng bringing more cutting-edge products to benefit patients. 🧠

#BiopharmaInnovation #ImmunotherapyAdvancement #TuoxinTianchengBiotech #chinesemedicine

• 1
• 2
• 3